Findings of Research Misconduct, 4267-4268 [2015-01427]
Download as PDF
asabaliauskas on DSK5VPTVN1PROD with NOTICES
Federal Register / Vol. 80, No. 17 / Tuesday, January 27, 2015 / Notices
interconnectedness, or the mix of
activities of the nonbank financial
company, could pose a threat to
financial stability. On April 11, 2012,
the Council published in the Federal
Register a final rule and interpretive
guidance (77 FR 21637), 12 CFR part
1310, that describe the manner in which
the Council intends to apply the
statutory standards and considerations,
and the processes and procedures the
Council intends to follow, in making
determinations under Section 113 of the
Dodd-Frank Act. The Council has made
final determinations regarding four
nonbank financial companies. The
Council uses information collected
under 12 CFR 1310.20 to assess whether
a nonbank financial company meets the
standards for a Council determination
under Section 113 of the Dodd-Frank
Act. The collection of information under
12 CFR 1310.21 affords a nonbank
financial company an opportunity to
submit materials to contest the
Council’s consideration of the company
for a proposed determination and to
contest a proposed determination. The
collection of information in 12 CFR
1310.22 provides a nonbank financial
company an opportunity to contest the
Council’s waiver or modification of the
notice or other procedural requirements
contained in 12 CFR 1310.21 by
requesting a hearing. The Council uses
information collected under 12 CFR
1310.23 in a reevaluation of its
determination regarding a nonbank
financial company subject to a Council
determination.
DATES: Written comments must be
received on or before March 30, 2015 to
be assured of consideration.
ADDRESSES: You may submit comments
by any of the following methods:
Mail: Attn: Request for Comments
(Financial Stability Oversight Council
Proposed Information Collection), Office
of the Financial Stability Oversight
Council, Department of the Treasury,
1500 Pennsylvania Avenue NW.,
Washington, DC 20220.
Electronic Submission:
FSOC.Comments@treasury.gov.
Instructions: All submissions received
must include the agency name and the
Federal Register document number that
appears at the end of this document.
Comments received will be made
available to the public via
regulations.gov without change, and
including any personal information
provided.
FOR FURTHER INFORMATION CONTACT:
Requests for additional information
about the filings or procedures should
be directed to Executive Director,
Financial Stability Oversight Council,
VerDate Sep<11>2014
18:01 Jan 26, 2015
Jkt 235001
Department of the Treasury, 1500
Pennsylvania Avenue NW., Washington,
DC 20220.
SUPPLEMENTARY INFORMATION:
Title: Determinations Regarding
Certain Nonbank Financial Companies.
OMB Control Number: 1505–0244.
Abstract: The Council uses
information collected under 12 CFR
1310.20 to assess whether a nonbank
financial company meets the standards
for a Council determination under
Section 113 of the Dodd-Frank Act. The
collection of information under 12 CFR
1310.21 affords a nonbank financial
company an opportunity to submit
materials to contest the Council’s
consideration of the company for a
proposed determination and to contest a
proposed determination. The collection
of information in 12 CFR 1310.22
provides a nonbank financial company
an opportunity to contest the Council’s
waiver or modification of the notice or
other procedural requirements
contained in 12 CFR 1310.21 by
requesting a hearing. The Council uses
information collected under 12 CFR
1310.23 in its reevaluation of a
determination regarding a nonbank
financial company subject to a Council
determination.
Type of Review: Extension of a
currently approved collection.
Affected Public: Nonbank financial
companies.
Estimated Total Annual Burden
Hours for all Collections: 500 hours.
Request for Comments: Comments
submitted in response to this notice will
be summarized or included in the
request for OMB approval. All
comments will become a matter of
public record. Comments are invited on:
(a) Whether the collection of
information is necessary for the proper
performance of the functions of the
agency, including whether the
information has practical utility; (b) the
accuracy of the agency’s estimate of the
burden of the collection of information;
(c) ways to enhance the quality, utility,
and clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology.
David G. Clunie,
Executive Secretary.
[FR Doc. 2015–00860 Filed 1–26–15; 8:45 am]
BILLING CODE 4810–25–P–P
PO 00000
Frm 00025
Fmt 4703
Sfmt 4703
4267
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
Notice is hereby given that
the Office of Research Integrity (ORI)
has taken final action in the following
case:
Dong Xiao, Ph.D., University of
Pittsburgh: Based on the report of an
inquiry conducted by the University of
Pittsburgh (UP), additional analysis
conducted by ORI in its oversight
review, and an admission by the
Respondent that he had ‘‘intentionally
fabricated data contained in a paper
entitled ‘Guggulsterone inhibits prostate
cancer growth via inactivation of Akt
regulated by ATP citrate signaling,’
specifically Figure 6G,’’ ORI found that
Dr. Dong Xiao, former Research
Assistant Professor, Department of
Urology, UP, engaged in research
misconduct in research supported by
National Cancer Institute (NCI),
National Institutes of Health (NIH),
grant R01 CA157477.
ORI found that Respondent engaged
in research misconduct by reporting
falsified data in Figures 1, 4, 5, S2, and
S3 in the following paper published
online:
• Gao, Y., Zeng, Y., Tian, J., Kslam,
M.S., Jiang, G., & Xiao, D.,
‘‘Gugglesterone inhibits prostate cancer
growth via inactivation of Akt regulated
by ATP citrate signaling.’’ Oncotarget,
June 26, 2014 [Epub ahead of print],
PMID: 24980815; hereafter referred to as
the ‘‘Oncotarget paper.’’
Specifically, in the Oncotarget paper,
Respondent:
• Falsely stated that 10 mice per group
were used to obtain data for tumor
volume (Figure 1A) and tumor weight
(Figure 1B) when data for only four
mice per group were available
• falsified the results for C-caspase 3
and phosphorylated Akt in the
Western blots presented in Figure 1D
to claim that treatment of tumor
bearing mice with Z-Gug significantly
enhanced C-capase 3 activity and
significantly inhibited Akt
phorphorylation, while the original
data showed no significant effect for
either activity
• falsified Figure 4C by manipulating pAkt bands to show that Z-Gug alone
and in combination with PHTM
significantly inhibited Akt
phosphorylation in PC3 and LNCaP
human prostate cancer cell lines; the
SUMMARY:
E:\FR\FM\27JAN1.SGM
27JAN1
asabaliauskas on DSK5VPTVN1PROD with NOTICES
4268
Federal Register / Vol. 80, No. 17 / Tuesday, January 27, 2015 / Notices
numbers above each band
representing the fold change human
prostate cancer cell lines; the numbers
above each band representing the fold
change in expression relative to the
DMSO control also were falsified for
p-ACLY (LNCaP cell line) and p-Akt
(PC3 and LNCaP cell lines) compared
to the values provided to the
Respondent
• falsified Figure 4D by substituting
bands for p-ACLY for those provided
to him to allow Respondent to claim
that Z-Gug significantly inhibited
phosphorylation of ACLY in lysates of
prostate tumors obtained from mice,
when the original data showed no
effect
• falsified Figures 5C and 5D to show
that treatment of PC3 and LNCaP cells
with Z-Gug alone and with Z-Gug
plus si-RNA targets to ACLY
stimulated Caspase 3/7 activity, when
the original data provided to him
showed no significant effect of either
treatment in PC3 cells and no effect of
Z-Gug alone in LNCaP cells
• falsified Figures 6G and 6H; these
figures purported to show that Nacetyl-L-cysteine (NAC), an inhibitor
of reactive oxygen species (ROS),
reversed the inhibition of Akt
phosphorylation caused by Z-Gug in
PC3 cells (Figure 6G) and LNCaP cells
(Figure 6G) when no Akt data for this
protocol was available to the
Respondent; Respondent admitted to
falsifying Figure 6G
• falsified Figures S2B and S3B by
altering data provided to him; these
experiments are complementary to
those shown in Figures 5C and 5D,
except that the effect of Z-Gug and Zgug plus si-RNA on Caspase 3/7
activity utilized on si-RNA was
directed to Akt activity. The original
data showed no significant effect of
either treatment in PC3 cells and no
effect of Z-Gug on LNCaP cells, while
both treatments were claimed to be
significant inducers of caspase
activity in both cell lines in the
published figures.
Dr. Xiao has entered into a Voluntary
Settlement Agreement (Agreement) and
has voluntarily agreed for a period of
three (3) years, beginning on December
23, 2014:
(1) To have his research supervised;
Respondent agreed to ensure that prior
to the submission of an application for
U.S. Public Health Service (PHS)
support for a research project on which
the Respondent’s participation is
proposed and prior to Respondent’s
participation in any capacity on PHSsupported research, the institution
employing him must submit a plan for
VerDate Sep<11>2014
18:01 Jan 26, 2015
Jkt 235001
supervision of his duties to ORI for
approval; the plan for supervision must
be designed to ensure the scientific
integrity of Respondent’s research
contribution; Respondent agreed that he
will not participate in any PHSsupported research until such a
supervision plan is submitted to and
approved by ORI; Respondent agreed to
maintain responsibility for compliance
with the agreed upon plan for
supervision;
(2) that any institution employing him
must submit, in conjunction with each
application for PHS funds, or report,
manuscript, or abstract involving PHSsupported research in which
Respondent is involved, a certification
to ORI that the data provided by
Respondent are based on actual
experiments or are otherwise
legitimately derived and that the data,
procedures, and methodology are
accurately reported in the application,
report, manuscript, or abstract; and
(3) to exclude himself voluntarily
from serving in any advisory capacity to
PHS including, but not limited to,
service on any PHS advisory committee,
board, and/or peer review committee, or
as a consultant.
FOR FURTHER INFORMATION CONTACT:
Acting Director, Office of Research
Integrity, 1101 Wootton Parkway, Suite
750, Rockville, MD 20852, (240) 453–
8200.
Donald Wright,
Acting Director, Office of Research Integrity.
[FR Doc. 2015–01427 Filed 1–26–15; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Notice of Interest Rate on Overdue
Debts
Section 30.18 of the Department of
Health and Human Services’ claims
collection regulations (45 CFR part 30)
provides that the Secretary shall charge
an annual rate of interest, which is
determined and fixed by the Secretary
of the Treasury after considering private
consumer rates of interest on the date
that the Department of Health and
Human Services becomes entitled to
recovery. The rate cannot be lower than
the Department of Treasury’s current
value of funds rate or the applicable rate
determined from the ‘‘Schedule of
Certified Interest Rates with Range of
Maturities’’ unless the Secretary waives
interest in whole or part, or a different
rate is prescribed by statute, contract, or
repayment agreement. The Secretary of
PO 00000
Frm 00026
Fmt 4703
Sfmt 4703
the Treasury may revise this rate
quarterly. The Department of Health and
Human Services publishes this rate in
the Federal Register.
The current rate of 101⁄2%, as fixed by
the Secretary of the Treasury, is certified
for the quarter ended December 31,
2014. This rate is based on the Interest
Rates for Specific Legislation, ‘‘National
Health Services Corps Scholarship
Program (42 U.S.C. 250(B)(1)(A))’’ and
‘‘National Research Service Award
Program (42 U.S.C. 288(c)(4)(B)).’’ This
interest rate will be applied to overdue
debt until the Department of Health and
Human Services publishes a revision.
Dated: January 15, 2015.
David C. Horn,
Director, Office of Financial Policy and
Reporting.
[FR Doc. 2015–01429 Filed 1–26–15; 8:45 am]
BILLING CODE 4150–04–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the Presidential Advisory
Council on HIV/AIDS
Office of the Assistant
Secretary for Health, Office of the
Secretary, Department of Health and
Human Services.
ACTION: Notice.
AGENCY:
As stipulated by the Federal
Advisory Committee Act, the U.S.
Department of Health and Human
Service (DHHS) is hereby giving notice
that the Presidential Advisory Council
on HIV/AIDS (PACHA) will hold a
meeting to discuss essential health
benefits and provider networks, the
integration of the Affordable Care Act
(ACA) qualified health plan and the
Ryan White Program; an update on the
National HIV/AIDS Strategy; and a
discussion on surveillance data. The
meeting will be open to the public.
DATES: The meeting will be held on
February 12, 2015, from 9 a.m. to
approximately 5 p.m. (ET) and February
13, 2015, from 9:30 a.m. to
approximately 12:30 p.m. (ET).
ADDRESSES: Renaissance Washington
DC, Downtown Hotel, 999 Ninth Street
NW., Washington, DC 20001.
FOR FURTHER INFORMATION CONTACT: Ms.
Caroline Talev, Public Health Analyst,
Presidential Advisory Council on HIV/
AIDS, U.S. Department of Health and
Human Services, 200 Independence
Avenue SW., Room 443H, Washington,
DC 20201; (202) 205–1178. More
detailed information about PACHA can
be obtained by accessing the PACHA
Web page on the AIDS.Gov Web site at
www.aids.gov/pacha.
SUMMARY:
E:\FR\FM\27JAN1.SGM
27JAN1
Agencies
[Federal Register Volume 80, Number 17 (Tuesday, January 27, 2015)]
[Notices]
[Pages 4267-4268]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-01427]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the Office of Research Integrity
(ORI) has taken final action in the following case:
Dong Xiao, Ph.D., University of Pittsburgh: Based on the report of
an inquiry conducted by the University of Pittsburgh (UP), additional
analysis conducted by ORI in its oversight review, and an admission by
the Respondent that he had ``intentionally fabricated data contained in
a paper entitled `Guggulsterone inhibits prostate cancer growth via
inactivation of Akt regulated by ATP citrate signaling,' specifically
Figure 6G,'' ORI found that Dr. Dong Xiao, former Research Assistant
Professor, Department of Urology, UP, engaged in research misconduct in
research supported by National Cancer Institute (NCI), National
Institutes of Health (NIH), grant R01 CA157477.
ORI found that Respondent engaged in research misconduct by
reporting falsified data in Figures 1, 4, 5, S2, and S3 in the
following paper published online:
Gao, Y., Zeng, Y., Tian, J., Kslam, M.S., Jiang, G., &
Xiao, D., ``Gugglesterone inhibits prostate cancer growth via
inactivation of Akt regulated by ATP citrate signaling.'' Oncotarget,
June 26, 2014 [Epub ahead of print], PMID: 24980815; hereafter referred
to as the ``Oncotarget paper.''
Specifically, in the Oncotarget paper, Respondent:
Falsely stated that 10 mice per group were used to obtain data
for tumor volume (Figure 1A) and tumor weight (Figure 1B) when data for
only four mice per group were available
falsified the results for C-caspase 3 and phosphorylated Akt
in the Western blots presented in Figure 1D to claim that treatment of
tumor bearing mice with Z-Gug significantly enhanced C-capase 3
activity and significantly inhibited Akt phorphorylation, while the
original data showed no significant effect for either activity
falsified Figure 4C by manipulating p-Akt bands to show that
Z-Gug alone and in combination with PHTM significantly inhibited Akt
phosphorylation in PC3 and LNCaP human prostate cancer cell lines; the
[[Page 4268]]
numbers above each band representing the fold change human prostate
cancer cell lines; the numbers above each band representing the fold
change in expression relative to the DMSO control also were falsified
for p-ACLY (LNCaP cell line) and p-Akt (PC3 and LNCaP cell lines)
compared to the values provided to the Respondent
falsified Figure 4D by substituting bands for p-ACLY for those
provided to him to allow Respondent to claim that Z-Gug significantly
inhibited phosphorylation of ACLY in lysates of prostate tumors
obtained from mice, when the original data showed no effect
falsified Figures 5C and 5D to show that treatment of PC3 and
LNCaP cells with Z-Gug alone and with Z-Gug plus si-RNA targets to ACLY
stimulated Caspase 3/7 activity, when the original data provided to him
showed no significant effect of either treatment in PC3 cells and no
effect of Z-Gug alone in LNCaP cells
falsified Figures 6G and 6H; these figures purported to show
that N-acetyl-L-cysteine (NAC), an inhibitor of reactive oxygen species
(ROS), reversed the inhibition of Akt phosphorylation caused by Z-Gug
in PC3 cells (Figure 6G) and LNCaP cells (Figure 6G) when no Akt data
for this protocol was available to the Respondent; Respondent admitted
to falsifying Figure 6G
falsified Figures S2B and S3B by altering data provided to
him; these experiments are complementary to those shown in Figures 5C
and 5D, except that the effect of Z-Gug and Z-gug plus si-RNA on
Caspase 3/7 activity utilized on si-RNA was directed to Akt activity.
The original data showed no significant effect of either treatment in
PC3 cells and no effect of Z-Gug on LNCaP cells, while both treatments
were claimed to be significant inducers of caspase activity in both
cell lines in the published figures.
Dr. Xiao has entered into a Voluntary Settlement Agreement
(Agreement) and has voluntarily agreed for a period of three (3) years,
beginning on December 23, 2014:
(1) To have his research supervised; Respondent agreed to ensure
that prior to the submission of an application for U.S. Public Health
Service (PHS) support for a research project on which the Respondent's
participation is proposed and prior to Respondent's participation in
any capacity on PHS-supported research, the institution employing him
must submit a plan for supervision of his duties to ORI for approval;
the plan for supervision must be designed to ensure the scientific
integrity of Respondent's research contribution; Respondent agreed that
he will not participate in any PHS-supported research until such a
supervision plan is submitted to and approved by ORI; Respondent agreed
to maintain responsibility for compliance with the agreed upon plan for
supervision;
(2) that any institution employing him must submit, in conjunction
with each application for PHS funds, or report, manuscript, or abstract
involving PHS-supported research in which Respondent is involved, a
certification to ORI that the data provided by Respondent are based on
actual experiments or are otherwise legitimately derived and that the
data, procedures, and methodology are accurately reported in the
application, report, manuscript, or abstract; and
(3) to exclude himself voluntarily from serving in any advisory
capacity to PHS including, but not limited to, service on any PHS
advisory committee, board, and/or peer review committee, or as a
consultant.
FOR FURTHER INFORMATION CONTACT: Acting Director, Office of Research
Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240)
453-8200.
Donald Wright,
Acting Director, Office of Research Integrity.
[FR Doc. 2015-01427 Filed 1-26-15; 8:45 am]
BILLING CODE 4150-31-P